DigestRedComo funciona
Red
/
Empresas
Ag
No verificado

Agenus Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

59 Comunicados de prensa

Ver todos los comunicados de prensa
21/01/2026
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
20/01/2026
Biotecnología
Salud
Oncología
Web y redes sociales
Agenus to Host First 2026 Stakeholder Webcast
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
15/01/2026
Ciencia
Biotecnología
Sanidad
Salud
Farmacéutica
Oncología
Mercado laboral
Industria
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
12/01/2026
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
23/12/2025
Industria
Biotecnología
Salud
Oncología
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
19/11/2025
Web y redes sociales
Biotecnología
Salud
Oncología
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
18/11/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Mercado laboral
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
10/11/2025
Biotecnología
VIH, SIDA y enfermedades autoinmunes
Salud
Medicina - Varios
Oncología
Web y redes sociales
Mercado de valores
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
05/11/2025
Web y redes sociales
Finanzas
Mercado de valores
Biotecnología
Salud
Oncología
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
17/10/2025
Biotecnología
Salud
Oncología
Eventos
Ferias y Congresos
Industria
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0